GlassScriptPhysician profile
Raymond A Plodkowski
NPI 1104831247
$545,520.05
in general payments reported to CMS, 2019-2025
36 companies · $119K in 2025
The $119K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $44K · 2021: $43K · 2022: $97K · 2023: $68K · 2024: $113K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $278K · Travel and Lodging: $13K · Food and Beverage: $9,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $277,985.39 |
| Travel and Lodging | $13,464.98 |
| Food and Beverage | $9,180.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $272,348.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $149,532.97 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58,504.62 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $35,946.29 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $15,677.57 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $10,467.73 | 2019-2025 | Contrave |
| Kvk-Tech, INC. | $421.67 | 2019-2024 | |
| Abbott Laboratories | $375.73 | 2019-2024 | Freestyle Libre 3 |
| Eisai INC. | $247.05 | 2019 | |
| Corcept Therapeutics | $215.42 | 2019-2020 | |
| Shire North American Group INC | $192.52 | 2019 | |
| Merck Sharp & Dohme LLC | $161.00 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $156.70 | 2019 | |
| Abbvie INC. | $121.86 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.75 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $119.83 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $117.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $113.37 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.07 | 2022 | |
| Madrigal Pharmaceuticals | $88.91 | 2025 | Rezdiffra |
| Vivus LLC | $62.39 | 2021-2024 | Qsymia |
| Ascendis Pharma Endocrinology INC | $54.41 | 2023-2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $47.45 | 2020 | |
| Ibsa Pharma INC. | $45.56 | 2020 | |
| Daiichi Sankyo INC. | $36.88 | 2019 | |
| Radius Health, INC. | $27.35 | 2024 | |
| Dexcom, INC. | $26.36 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $24.20 | 2021 | |
| Ethicon US, LLC | $23.63 | 2024 | Linx Reflux Management System |
| Sequel Med Tech, LLC | $23.56 | 2025 | Twiist |
| Medtronic, INC. | $23.51 | 2024 | Minimed 780g |
| Companion Medical, INC. | $22.83 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.65 | 2019 | |
| Insulet Corporation | $19.86 | 2020 | |
| Amgen INC. | $18.77 | 2019 | |
| Becton, Dickinson and Company | $18.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Plodkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.